Uterine Serous Carcinoma and Uterine Carcinosarcoma: Molecular Features, Clinical Advances, and Emerging Therapies

Abstract: Endometrial cancer, including high-grade subtypes, has a rising incidence and mortality. Uterine serous carcinoma (USC) and uterine carcinosarcoma (UCS) make up a small but increasing […]

Pilot Data on Axicabtagene Ciloleucel for CNS Lymphoma

H&O  Could you describe the impetus for and design of your pilot study on axicabtagene ciloleucel for CNS lymphoma? CJ  When lymphomas that involve the central […]

Can Unresectable Non–Small Cell Lung Cancer Become Resectable?

H&O  What is the definition of resectable disease in non–small cell lung cancer (NSCLC)? JC  The definition of resectable disease is based on the determination of […]

Update on CDK4/6 Inhibitors in Breast Cancer

H&O  Which breast cancer patients are eligible for treatment with a CDK4/6 inhibitor? ST  CDK4/6 inhibitors, which include palbociclib (Ibrance, Pfizer), ribociclib (Kisqali, Novartis), and abemaciclib […]

The Approval of Lisocabtagene Maraleucel in Chronic Lymphocytic Leukemia

H&O When did lisocabtagene maraleucel first receive approval? WW The US Food and Drug Administration (FDA) first approved lisocabtagene maraleucel (liso-cel; Breyanzi, Bristol Myers Squibb) on […]

Efficacy and Safety of NTRK Inhibitors in Patients With NTRK Fusion–Positive Lung and Thyroid Cancers

Abstract: Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are implicated in various cancers, including those of the lung and thyroid. The prevalence of NTRK fusions is 0.1 […]

View More Issues